Skip to main content

Chronic treatment with a long-acting somatostatin analogue in a patient with intestinal carcinoid tumor: occurence of cholelithiasis

Abstract

The long-acting somatostatin analogue SMS 201-995 has been used efficaciously in the therapy of metastatic carcinoid tumor, vasoactive intestinal peptide producing islet cell carcinoma, acromegaly, and TSH secreting pituitary tumors. We report the development of a gallstone in a patient treated for 23 months with a long acting somatostatin analogue for a metastatic carcinoid tumor. Symptomatic improvement and a reduction in the urinary excretion of 5-hydroxyin-doleacetic acid occurred. There was no evidence of a gallstone on ultrasound and CT scan of the abdomen prior to somatostatin therapy. A progressively enlarging, asymptomatic gallstone developed during therapy.

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Grahame Smith D.G. The carcinoid syndrome. In: De Groot L.J. (Ed.), Endocrinology. Grune & Stratton, Inc., New York, 1979, p. 1721.

    Google Scholar 

  2. 2.

    Antonelli A., Del Guerra P., Fierabracci A., Gori E., Baschieri L. Effect of salmon calcitonin on symptoms and urinary excretion of 5 hydroxyindoleacetic acid in the carcinoid syndrome. Br. Med. J. 235: 961, 1987.

    Article  Google Scholar 

  3. 3.

    Kvols L.K., Martin J.K., Marsh H.M., Moertel C.G. Rapid reversal of carcinoid crisis with a somatostatin analogue. N. Engl. J. Med. 373: 1229, 1985.

    Google Scholar 

  4. 4.

    Kvols L.K., Moertel C.G., O’Connell M.J., Schutt A.J., Rubin J., Hahn R.G. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N. Engl. J. Med. 375: 663, 1986.

    Article  Google Scholar 

  5. 5.

    Comi R.J., Gesundheit N., Murray L., Gorden P., Weintraub B.D. Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue. N. Engl. J. Med. 317: 12, 1987.

    CAS  PubMed  Article  Google Scholar 

  6. 6.

    Tauber J.P., Babin Th., Tauber M.T., Vigoni F., Bonafe A., Ducasse M., Harris A.G., Bayard F. Long term effects of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acromegaly. J. Clin. Endocrinol. Metab. 68: 917, 1989.

    CAS  PubMed  Article  Google Scholar 

  7. 7.

    Moertel C.G. An odissey in the land of small tumors. J. Clin. Oncol. 5: 1503, 1987.

    Google Scholar 

  8. 8.

    Lamberts S.W.J., Tilanus H.W., Klooswijk A.I.J., Banning H.A., Van der Lely A.J., De Jong F.H. Successfull treatment with SMS 201-995 of Cushing’s syndrome caused by ectopic adrenocorticotropin secretion from a metastatic gastrin-secreting pancreatic islet cell carcinoma. J. Clin. Endocrinol. Metab. 67: 1080, 1988.

    CAS  PubMed  Article  Google Scholar 

  9. 9.

    Lamberts S.W.J. Clinical use of somatostatin analogues. Acta Endocrinol. (Copenh) 116 (Suppl. 286): 9, 1987.

    Google Scholar 

  10. 10.

    Kraenzlin M.E., Ch’ing J.L.C., Wood S.M., Carr D.H., Bloom S.R. Long term treatment of a Vipoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology 88: 185, 1985.

    CAS  PubMed  Article  Google Scholar 

  11. 11.

    Reubi J.C. A somatostatin analogue inhibits chondrosarcoma and insulinoma tumor growth. Acta Endocrinol. (Copenh) 109: 108, 1985.

    CAS  Google Scholar 

  12. 12.

    Krenning E.P., Bakker W.H., Breeman W.A.P., Koper J.W., Kooij P.P.M., Ausema L., Lameris J.S., Reubi J.C., Lamberts S.W.J. Localisation of endocrine-related tumors with ra-dioiodinated analogue of somatostatin. Lancet 1: 4, 1989.

    Google Scholar 

  13. 13.

    Sjoerdsma A. Clinical and laboratory features of malignant carcinoid. Arch. Inter. Med. 102: 936, 1958.

    CAS  Article  Google Scholar 

  14. 14.

    Friesen H.R. Tumor of the endocrine pancreas. N. Engl. J. Med. 306: 580, 1982.

    CAS  PubMed  Article  Google Scholar 

  15. 15.

    Van Liessum P.A., Hopman W.P.M., Pieters G.F.F.M., Jansen J.B.M.J., Smals A.G.H., Rosenbusch G., Kloppenborg P.W.C., Lamers C.B.H.W. Postprandial gallbladder motility during long term treatment with the long-acting somatostatin analog SMS 201-995 in acromegaly. J. Clin. Endocrinol. Metab. 69: 557, 1989.

    PubMed  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Elio Roti.

Additional information

This work was supported in part by grant 85.00533.04,86.00134.04 and 88.00628.04 from Consiglio Nazionale delle Ricerche, Rome, by grant “Patologia delta Tiroide. Indagine dei Fattori Etiopatogenetici” of Ministero Pubblica Istruzione 40%, Rome, Italy, by grant DK-19819 from NIDDK, NIH, Bethesda, MD, and by NATO grant RG. 85/0696.

Dr. Eliana Gardini is a recipient of a fellowship from Associazione Volontaria Promozione Ricerca Tumori (A.VO.PRO.RI.T.), Parma, Italy.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Roti, E., Minelli, R., Gardini, E. et al. Chronic treatment with a long-acting somatostatin analogue in a patient with intestinal carcinoid tumor: occurence of cholelithiasis. J Endocrinol Invest 13, 69–72 (1990). https://doi.org/10.1007/BF03348589

Download citation

Key-words

  • Carcinoid tumor
  • SMS 201-995
  • cholelithiasis